TITLE

Invasive Aspergillosis in Liver Transplant Recipients: Outcome Comparison of Therapy with Amphotericin B Lipid Complex and a Historical Cohort Treated with Conventional Amphotericin B

AUTHOR(S)
Linden, Peter K.; Coley, Kim; Fontes, Paolo; Fung, John J.; Kusne, Shimon
PUB. DATE
July 2003
SOURCE
Clinical Infectious Diseases;7/1/2003, Vol. 37 Issue 1, p17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Invasive aspergillosis (IA) in liver transplant recipients is associated with poor response rates and a very high mortality rate, despite administration of therapy with conventional amphotericin B. We conducted a single-center, retrospective study to compare the outcome of liver transplant recipients with IA who received amphotericin B lipid complex (ABLC) or conventional amphotericin B. IA was present in 12 ABLC-treated patients (definite, 4; probable, 8) and 29 amphotericin B recipients (definite, 11; probable, 18) in the historical cohort. The 60-day mortality rate was lower in the ABLC cohort: 4 (33%) of 12 patients versus 24 (83%) of 29 patients (P = .006). Only 1 of 4 ABLC recipients with definite IA died, compared with all 11 in the amphotericin B group. Sixty-day survival probability curves was significantly lower in the amphotericin B cohort (P = .008). ABLC therapy was the only independent mortality-protective variable (odds ratio, 0.31; 95% confidence interval, 0.07-0.44; P = .02). First-line or early salvage therapy for IA with ABLC was associated with significantly improved survival relative to a comparable historical group treated with amphotericin B.
ACCESSION #
10361848

 

Related Articles

  • Successful Treatment of Paecilomyces variotii Peritonitis in a Liver Transplant Patient. Polat, Meltem; Kara, Soner; Tapısız, Anıl; Demirtaş, Zeliha; Sarı, Sinan; Kalkancı, Ayşe; Tezer, Hasan; Dalgıç, Buket // Mycopathologia;Apr2015, Vol. 179 Issue 3/4, p317 

    Paecilomyces variotii has previously been reported as a causative pathogen for peritonitis in patients on continuous ambulatory peritoneal dialysis and shown to be usually sensitive to amphotericin B and resistant to voriconazole. We report the first case, to our knowledge, of P. variotii...

  • Delaying Amphotericin B-Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis. Chamilos, Georgios; Lewis, Russell E.; Kontoyiannis, Dimitrios P. // Clinical Infectious Diseases;8/15/2008, Vol. 47 Issue 4, p503 

    Background. Zygomycosis is an emerging opportunistic mycosis among immunocompromised patients with a particularly poor prognosis. Methods. We analyzed the impact of delaying effective amphotericin B-based therapy on outcome among 70 consecutive patients with hematologic malignancy who had...

  • Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Böhme, Angelika; Ruhnke, Markus; Buchheidt, Dieter; Cornely, Oliver; Einsele, Herrmann; Enzensberger, Ruxandra; Hebart, Holger; Heinz, Werner; Junghanss, Christian; Karthaus, Meinolf; Krüger, William; Krug, Utz; Kubin, Thomas; Penack, Olaf; Reichert, Dietmar; Reuter, Stefan; Silling, Gerda; Südhoff, Thomas; Ullmann, Andrew; Maschmeyer, Georg // Annals of Hematology;Feb2009, Vol. 88 Issue 2, p97 

    Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to...

  • Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome. Patterson, Thomas F.; Boucher, Helen W.; Herbrecht, Raoul; Denning, David W.; Lortholary, Olivier; Ribaud, Patricia; Rubin, Robert H.; Wingard, John R.; DePauw, Ben; Schlamm, Haran T.; Troke, Peter; Bennett, John E. // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1448 

    Background. In a previous randomized trial of voriconazole versus amphotericin B deoxycholate for primary therapy of invasive aspergillosis, voriconazole demonstrated superior efficacy and better survival. In that trial, treatment with voriconazole or amphotericin B deoxycholate could be...

  • Percutaneous treatment with amphotericin B of mycotic lung lesions from invasive aspergillosis: results in 10 immunocompromised patients. Veltri, A.; Anselmetti, G. C.; Bartoli, G.; Martina, M. C.; Regge, D.; Galli, J.; Bertini, M. // European Radiology;Dec2000, Vol. 10 Issue 12, p1939 

    The aim of this study was to evaluate the efficacy of percutaneous treatment of pulmonary lesions from invasive aspergillosis in immunocompromised patients. From 1992 to 1998, ten patients (seven men and three women; mean age 56 years) affected by hematological neoplasms (8 acute myeloid...

  • Prednisolone.  // Reactions Weekly;7/26/2008, Issue 1212, p24 

    The article describes the case of a 24-year-old man who developed fatal pulmonary and cerebral aspergillosis during treatment with prednisolone for thrombocytopenic purpura. The patient started receiving IV prednisolone following diagnosis of idiopathic thrombocytopenic purpura. Five weeks after...

  • Safety of high-dose Amphotericin B lipid complex. Singhal, S; Hastings, J G M; Mutimer, D J // Bone Marrow Transplantation;7/1/99, Vol. 24 Issue 1, p116 

    Talks about the use of amphotericin B for the treatment of aspergillus infections. Brief information on amphotericin B lipid complex (Abelcet); Details on toxicity associated with the use of high-dose Abelcet.

  • Practice Guidelines for Diseases Caused by Aspergillus. Stevens, David A.; Kan, Virginia L.; Judson, Marc A.; Morrison, Vicki A.; Dummer, Stephen; Denning, David W.; Bennett, John E.; Walsh, Thomas J.; Patterson, Thomas F.; Pankey, George A. // Clinical Infectious Diseases;4/1/2000, Vol. 30 Issue 4, p696 

    Executive Summary Aspergillosis comprises a variety of manifestations of infection. These guidelines are directed to 3 principal entities: invasive aspergillosis, involving several organ systems (particularly pulmonary disease); pulmonary aspergilloma; and allergic bronchopulmonary...

  • Pulmonary Aspergillosis in Childhood. Berger, Ira; Phillips, Walter L.; Shenker, I. Ronald // Clinical Pediatrics;Mar1972, Vol. 11 Issue 3, p178 

    An adolescent girl with aspergillosis is presented who demonstrated three different manifestations of the disease process. Therapy included the use of Amphotericin B and two pulmonary resections for aspergillosis. The patient has been stable for one and a half years without any evidence of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics